. 2022 May 3;198(6):507–526. doi: 10.1007/s00066-022-01942-1

Table 8.

Trials evaluating PARP inhibitors as radiosensitizers, sorted by publication year

Author	Year	Agent	Dose	n	Radiation regimen	Results
Su et al. [54]	2014	Veliparib	20–30 mg/m²/dose bid	31 (3)	N/A	Overall tolerable combination with TMZ, increased hematotoxicity
Su et al. [54]	2014	+ TMZ (partially)	180 mg/m²/day	31 (3)	N/A
Lesueur et al. [61]	2019	Olaparib	50–200 mg bid	79	60 Gy in 30 fractions	Trial ongoing, evaluating feasibility and outcome of RT + TMZ + PARPi
Lesueur et al. [61]	2019	+TMZ	75 mg/m²	79	60 Gy in 30 fractions
Sim et al. [60]	2021	Veliparib	200 mg bid	125	60 Gy in 30 fractions	Median OS: 12.7 (RT + TMZ + PARPi) vs 12.8 months (RT + TMZ alone) Feasibility of RT + adjuvant TMZ + PARPi

n = number of patients included (number of patients with glioblastoma in parentheses if multiple entities were included)